Sensitivity of the Step Test to Detect Improvement in Dyspnea Following Bronchodilation in Patients With Chronic Obstructive Pulmonary Disease (CODEx)
During the previous phases of the project (Phase I and II), two new field tests have been designed and validated for an integration in a primary care setting in Chronic Obstructive Pulmonary Disease (COPD). These new field tests are 3-min paced-walk test (3MPWT) and 3-min paced step test (3MPST). If the validity and sensitivity of the TM3 could be highlighted, particularly by the reduction of dyspnea level following bronchodilatation, Phase II highlight that the 3MPST does not allow to detect this decrease of dyspnea after bronchodilatation. The use of too high step rates could explain these results through a hypothesis relative to neuromechanical coupling of dyspnea. The main objective of this trial is to follow the investigations on the sensitivity of 3MPST to detect the effects of pharmacological intervention on the exertional dyspnea in COPD patient. The hypothesis of this work is that the use of lower step rates cadences could allow to detect an improvement of exertional dyspnea following treatment-induced bronchodilatation, contrary to higher step rates.
Moderate Chronic Obstructive Pulmonary Disease
Severe Chronic Obstructive Pulmonary Disease
Drug: Combination ipratropium/salbutamol or placebo (nebulization)
|Study Design:||Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Outcomes Assessor)
Primary Purpose: Diagnostic
|Official Title:||Measurement of Exertional Dyspnea in the Primary Care Setting in Patients With COPD, Phase III: Sensitivity of the Step Test to Detect Improvement in Dyspnea Following Bronchodilation in Patients With COPD|
- Symptom perception [ Time Frame: change from baseline in Borg Scale at 3 min of exercise ] [ Designated as safety issue: No ]Patients will be asked to score their dyspnea and leg discomfort perception using a 10-point Borg scale.
- Cardiac and ventilatory outcomes [ Time Frame: Change from baseline at 3 minutes of exercise ] [ Designated as safety issue: No ]Metabolic, cardiac and ventilatory parameters will be measured using a portable telemetric system. Principal outcomes will be oxygen uptake (VO2), carbon dioxide output (VCO2), ventilation (VE), breathing frequency (BF), tidal volume (Vt) and heart rate (HR).
- Inspiratory capacity [ Time Frame: Change from baseline at the end of the exercise. ] [ Designated as safety issue: No ]Inspiratory capacity will be measured at rest and at the end of the 3-min step test (immediately following the assessment of dyspnea at 3 minutes).
- Pleural pressure [ Time Frame: Change from baseline at 1, 2 and 3 minutes of exercise ] [ Designated as safety issue: No ]Tidal excursion in pleural pressure will be measured using an oesophageal balloon-catheter system that will be positioned using standardized technique10. Oesophageal pressure signal will be sampled at a rate of 100 Hz.
- Pulmonary function [ Time Frame: At baseline and 60-min after the nebulization of either placebo and bronchodilator ] [ Designated as safety issue: No ]Pulmonary function will be measured by spirometry and plethysmography in the initial visit. In the subsequent visits, pulmonary function will be evaluated by spirometry before and 60-min after the nebulization of either placebo or bronchodilator.
- Maximal oxygen consumption [ Time Frame: Change from baseline at 1, 2 and 3 minutes of exercise ] [ Designated as safety issue: No ]Exercise capacity will be directly assessed following an incremental cycle exercise test. The exercise capacity was defined as the maximal oxygen consumption (VO2 peak, ml/kg/min) by direct measurements of gas exchanges.
- Maximal inspiratory pressure (PImax) [ Time Frame: Change from baseline after 3 minutes of exercise ] [ Designated as safety issue: No ]The maximum inspiratory pressure (PImax) will be measured during a sniff manoeuvre. These measurements will allow to construct the ratio of respiratory effort (tidal Pes/PImax) to thoracic displacement (VT/predicted VC), an index of neuromechanical coupling
|Study Start Date:||September 2012|
|Estimated Study Completion Date:||July 2013|
|Estimated Primary Completion Date:||July 2013 (Final data collection date for primary outcome measure)|
Experimental: COPD group
Moderate and/or severe COPD patients, corresponding to GOLD stages II and III.
Drug: Combination ipratropium/salbutamol or placebo (nebulization)
For the visit 2, COPD patients will be randomly assigned a combination of ipratropium/salbutamol or a placebo in a double-blind crossover design. For the visit 3, the other intervention drug will be assigned. The bronchodilation obtained with the medication will allow to determine if the 3-min step test is sensitive by detecting an improvement of exertional dyspnea following bronchodilation.
Other Name: Combivent or placebo (nebulization)
For this project, 40 patients with COPD will be recruited in 2 centres (in the Institute of Cardiology and Pneumology of Quebec and in the Chest Institute of Montreal). For each patient, three visits will be performed. During the first visit, baseline pulmonary function and maximal exercise capacity will be evaluated and the patients will be familiarized with step test proceedings. Between the different visits, a 3-7 days period will be respected. During the second and the third visits, 4 step tests will be performed at 4 different rates, following one of the two conditions (placebo or bronchodilatation). This project will propose two randomization levels. The first randomization will be relative to the choice of the condition used during the second visit (placebo ou bronchodilatation) and the second one for the rates order (14, 16, 20, 24 steps/min). During each performed exercise, cardiorespiratory and pulmonary parameters will be measured using a portable system.
|Contact: François Maltais, M.D||418-656-4747||Francois.Maltais@fmed.ulaval.ca|
|Contact: Benoit Borel, Ph.D||418-656-8711 ext email@example.com|
|Montreal Chest Institute - McGill University||Recruiting|
|Montréal, Quebec, Canada|
|Contact: Jean Bourbeau, M.D firstname.lastname@example.org|
|Contact: Hélène Perrault, Ph.D email@example.com|
|Sub-Investigator: Jean Bourbeau, M.D|
|Institut Universitaire de Cardiologie et de Pneumologie de Québec - Université Laval||Recruiting|
|Québec, Quebec, Canada|
|Contact: Benoit Borel, Ph.D 4186568711 ext 3995 firstname.lastname@example.org|
|Principal Investigator: François Maltais, M.D|
|Principal Investigator:||François Maltais, M.D||Institut Universitaire de Cardiologie et de Pneumologie de Québec - Université Laval|